Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction: Role of Type 2 diabetes mellitus

Table 2 Baseline characteristics and therapy of non-diabetic patients based on quartiles of admission heart rate (Q1-Q4)

	Patients without T2DM (n = 6474)				P-value	Patients with T2DM (n = 820)				P-value
	Q1 (n = 1766)	Q2 (n = 1696)	Q3 (n = 1518)	Q4 (n = 1494)	P-value	Q1 (n = 180)	Q2 (n = 175)	Q3 (n = 193)	Q4 (n = 272)	P-value
Females, %	25.3	25.5	26.8	31.3	<0.001	37.8	43.4	42.0	47.1	0.270
Age	62.3 ± 11.2	61.2 ± 11.9	61.7 ± 12.2	63.0 ± 12.9	<0.001	64.5 ± 9.9	64.0 ± 9.5	64.8 ± 10.2	65.3 ± 9.9	0.313
Systolic blood pressure	120.0 ± 24.0	128.0 ± 24.0	130.4 ± 23.3	128.5 ± 28.0	<0.001	120.2 ± 26.8	130.2 ± 22.0	130.6 ± 25.2	130.1 ± 27.4	<0.001
Anterior ST Elevation, %	34.4	51.6	62.7	68.5	<0.001	27.2	50.3	57.5	67.3	<0.001
Killip class ≥2, %	13.5	12.6	14.0	29.7	<0.001	15.6	13.7	20.2	41.2	<0.001
Glucose, mmol/L	7.8 ± 3.5	7.7 ± 3.2	7.8 ± 3.5	8.4 ± 4.2	0.097	13.0 ± 5.3	12.6 ± 5.0	12.8 ± 4.8	14.1 ± 6.2	0.054
Previous medical history
Hypertension, %	36.4	36.9	38.7	42.6	0.001	55.6	53.1	53.9	64.0	0.062
Myocardial Infarction, %	7.3	6.5	6.8	9.6	0.005	6.7	9.7	11.9	17.7	0.003
Heart failure, %	1.0	1.2	2.0	5.0	<0.001	3.3	3.4	4.7	11.4	<0.001
Stroke, %	8.5	7.6	8.0	9.5	0.235	12.2	18.9	14.0	19.5	0.125
Therapeutic measures
PCI, %	10.4	12.4	11.7	9.2	0.024	16.7	20.0	21.8	11.8	0.023
Thrombolytic therapy, %	57.6	54.7	54.2	45.6	<0.001	53.3	45.1	40.4	43.0	0.068
Insulin, %	11.4	9.5	11.8	13.8	0.002	42.8	37.1	37.9	42.3	0.548
β-blockers, %	45.8	67.3	69.5	68.0	<0.001	42.8	73.1	66.8	68.0	<0.001
ACEI, %	68.3	74.3	73.1	71.8	<0.001	63.3	73.1	75.7	78.3	0.004
Lipid-lowering drugs, %	69.7	73.6	71.6	69.3	0.023	71.7	76.0	73.1	70.6	0.644

PCI, Percutaneous coronary intervention; ACEI, Angiotensin-converting enzyme inhibitors; P-values are given for the comparison of between the different quartiles of heart rate.

ISSN: 1471-2261